Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

July 30, 2008

Primary Completion Date

September 15, 2009

Study Completion Date

September 19, 2018

Conditions
Ovarian Neoplasms
Interventions
DRUG

AZD2281

400mg Oral twice daily

DRUG

Liposomal Doxorubicin

50mg/m2 Monthly Intravenous

DRUG

AZD2281

200mg oral twice daily

Trial Locations (24)

2031

Research Site, Randwick

3000

Research Site, Leuven

3002

Research Site, East Melbourne

10065

Research Site, New York

22185

Research Site, Lund

31096

Research Site, Haifa

33428

Research Site, Boca Raton

50937

Research Site, Cologne

52621

Research Site, Ramat Gan

77030

Research Site, Houston

81377

Research Site, München

90048

Research Site, Los Angeles

94115

Research Site, San Francisco

6423906

Research Site, Tel Aviv

02115

Research Site, Boston

VIC 3050

Research Site, Melbourne, Parkville

70-111

Research Site, Szczecin

08035

Research Site, Barcelona

08907

Research Site, Hospitalet deLlobregat

CB2 0QQ

Research Site, Cambridge

EH4 2XR

Research Site, Edinburgh

SE1 9RT

Research Site, London

M20 4BX

Research Site, Manchester

SM2 5PT

Research Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY